Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2765513 | 0.84 | SIGMAR1 (0.65) | MAPTNPSR1HTR1ADRD2SIGMAR1 | |
| SCHEMBL2766286 | 0.84 | HTR1A (0.61) | MAPTNPSR1HTR1ADRD2SIGMAR1 | |
| SCHEMBL2767412 | 0.82 | MAPT (0.63) | MAPTNPSR1HTR1ADRD2SIGMAR1 | |
| SCHEMBL19381355 | 0.81 | HTR1A (0.57) | MAPTNPSR1HTR1ADRD2SIGMAR1 | |
| SCHEMBL2766366 | 0.80 | HTR1A (0.78) | MAPTNPSR1HTR1ADRD2SIGMAR1 | |
| SCHEMBL3482309 | 0.80 | SIGMAR1 (0.69) | MAPTNPSR1HTR1ADRD2SIGMAR1 | |
| SCHEMBL7990044 | 0.79 | KCNH2 (0.72) | MAPTNPSR1HTR1ADRD2SIGMAR1 | |
| SCHEMBL6509439 | 0.77 | DRD2 (1.00) | MAPTNPSR1HTR1ADRD2SIGMAR1 | |
| SCHEMBL23244333 | 0.76 | ME2 (0.67) | MAPTNPSR1MEN1ALDH1A1KMT2A | |
| SCHEMBL29577255 | 0.76 | ME2 (0.67) | MAPTNPSR1MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1627871-B1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-7449466-B2 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1627871-A1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | SHBG, STS, ARSA | MAPT 4852/4885NPSR1 434/4885HTR1A 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.